MBRK Middlebrook Pharmaceuticals (MM)

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on developing and commercializing anti-infective products that fulfill unmet medical needs. We have developed a proprietary delivery technology called PULSYS�, which enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. We are currently developing a portfolio of anti-infective PULSYS products. Our near-term corporate strategy is to improve dosing regimens and/or reduce frequency of dosing which we believe will result in improved patient dosing convenience and compliance for antibiotics that have been used and trusted by physicians and patients for decades. MiddleBrook currently markets KEFLEX, the immediate-release brand of cephalexin, and MOXATAG � the first and only FDA-approved once-daily amoxicillin. For more information about MiddleBrook, please visit www.middlebrookpharma.com.

Company:

� MiddleBrook Pharmaceuticals, Inc. �

Headquarters Address:

7 Village Circle Suite 100 Westlake, TX 76262 �

Main Telephone:

817-837-1200 �

Website:

www.middlebrookpharma.com

�

Ticker/ISIN:

MBRK(NASDAQ)/US5960871060 �

Type of Organization:

Public � Industry: Pharmaceutical �

Key Executives:

CEO: John Thievon

CFO: David Becker

�

Investor Relations

Contact:

Faith Pomeroy-Ward

Phone:

817-837-1208

Email:

faith@middlebrookpharma.com